Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 20.8
(1.51%)
CNY 20.8
(1.51%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -322.77 Million CNY | -69.42% |
| 2022 | 1.03 Billion CNY | -39.9% |
| 2021 | 1.72 Billion CNY | 6.39% |
| 2020 | 1.62 Billion CNY | 7.2% |
| 2019 | 1.51 Billion CNY | 28.27% |
| 2018 | 1.18 Billion CNY | 26.91% |
| 2017 | 930.06 Million CNY | 28.55% |
| 2016 | 723.51 Million CNY | 18.25% |
| 2015 | 611.86 Million CNY | 28.52% |
| 2014 | 476.08 Million CNY | 20.71% |
| 2013 | 394.39 Million CNY | 38.95% |
| 2012 | 283.84 Million CNY | 100.88% |
| 2011 | 141.29 Million CNY | 13.2% |
| 2010 | 124.81 Million CNY | 64.56% |
| 2009 | 75.85 Million CNY | 124.85% |
| 2008 | 33.73 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 45.24 Million CNY | 29.29% |
| 2024 Q3 | 51.57 Million CNY | 13.99% |
| 2024 Q1 | 34.99 Million CNY | 192.66% |
| 2023 Q1 | 199.11 Million CNY | 32.93% |
| 2023 Q2 | 113.55 Million CNY | -42.97% |
| 2023 FY | 317.37 Million CNY | -69.42% |
| 2023 Q3 | 42.47 Million CNY | -62.59% |
| 2023 Q4 | -37.77 Million CNY | -188.92% |
| 2022 Q3 | 291.14 Million CNY | -4.71% |
| 2022 FY | 1.03 Billion CNY | -39.9% |
| 2022 Q4 | 149.79 Million CNY | -48.55% |
| 2022 Q2 | 305.54 Million CNY | 4.89% |
| 2022 Q1 | 291.29 Million CNY | -30.27% |
| 2021 Q1 | 434.72 Million CNY | -4.53% |
| 2021 FY | 1.72 Billion CNY | 6.39% |
| 2021 Q3 | 443.75 Million CNY | 3.05% |
| 2021 Q2 | 430.62 Million CNY | -0.94% |
| 2021 Q4 | 417.73 Million CNY | -5.86% |
| 2020 FY | 1.62 Billion CNY | 7.2% |
| 2020 Q1 | 306.94 Million CNY | -32.56% |
| 2020 Q4 | 455.34 Million CNY | 0.0% |
| 2020 Q3 | 455.33 Million CNY | 12.29% |
| 2020 Q2 | 405.51 Million CNY | 32.11% |
| 2019 Q2 | 314.47 Million CNY | -3.88% |
| 2019 FY | 1.51 Billion CNY | 28.27% |
| 2019 Q1 | 327.16 Million CNY | -10.71% |
| 2019 Q3 | 417.32 Million CNY | 32.71% |
| 2019 Q4 | 455.16 Million CNY | 9.07% |
| 2018 Q1 | 234.87 Million CNY | -26.43% |
| 2018 Q2 | 263.55 Million CNY | 12.21% |
| 2018 Q4 | 366.39 Million CNY | 16.11% |
| 2018 Q3 | 315.56 Million CNY | 19.74% |
| 2018 FY | 1.18 Billion CNY | 26.91% |
| 2017 Q3 | 242.52 Million CNY | 20.26% |
| 2017 FY | 930.06 Million CNY | 28.55% |
| 2017 Q1 | 166.61 Million CNY | -12.98% |
| 2017 Q4 | 319.25 Million CNY | 31.64% |
| 2017 Q2 | 201.67 Million CNY | 21.04% |
| 2016 Q4 | 191.46 Million CNY | -5.44% |
| 2016 FY | 723.51 Million CNY | 18.25% |
| 2016 Q1 | 148.6 Million CNY | -25.28% |
| 2016 Q3 | 202.49 Million CNY | 11.9% |
| 2016 Q2 | 180.94 Million CNY | 21.77% |
| 2015 Q1 | 126.08 Million CNY | -10.5% |
| 2015 Q4 | 198.88 Million CNY | 30.94% |
| 2015 Q3 | 151.88 Million CNY | 12.5% |
| 2015 Q2 | 135.01 Million CNY | 7.08% |
| 2015 FY | 611.86 Million CNY | 28.52% |
| 2014 Q4 | 140.88 Million CNY | 12.11% |
| 2014 FY | 476.08 Million CNY | 20.71% |
| 2014 Q1 | 90.8 Million CNY | -24.02% |
| 2014 Q2 | 118.72 Million CNY | 30.75% |
| 2014 Q3 | 125.66 Million CNY | 5.84% |
| 2013 Q4 | 119.51 Million CNY | 34.1% |
| 2013 FY | 394.39 Million CNY | 38.95% |
| 2013 Q1 | 75.32 Million CNY | -17.9% |
| 2013 Q2 | 110.42 Million CNY | 46.6% |
| 2013 Q3 | 89.12 Million CNY | -19.29% |
| 2012 Q3 | 72 Million CNY | -0.1% |
| 2012 Q2 | 72.07 Million CNY | 50.14% |
| 2012 Q1 | 48 Million CNY | 37.65% |
| 2012 FY | 283.84 Million CNY | 100.88% |
| 2012 Q4 | 91.75 Million CNY | 27.43% |
| 2011 Q3 | 25.62 Million CNY | -47.52% |
| 2011 Q4 | 34.87 Million CNY | 36.11% |
| 2011 FY | 141.29 Million CNY | 13.2% |
| 2011 Q2 | 48.82 Million CNY | 52.69% |
| 2011 Q1 | 31.97 Million CNY | -17.47% |
| 2010 Q3 | 28.7 Million CNY | 0.0% |
| 2010 FY | 124.81 Million CNY | 64.56% |
| 2010 Q4 | 38.74 Million CNY | 35.0% |
| 2009 FY | 75.85 Million CNY | 124.85% |
| 2008 FY | 33.73 Million CNY | 0.0% |